<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342546</url>
  </required_header>
  <id_info>
    <org_study_id>PROICM 2019-07 PRE</org_study_id>
    <secondary_id>2019-A02178-49</secondary_id>
    <nct_id>NCT04342546</nct_id>
  </id_info>
  <brief_title>Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction</brief_title>
  <acronym>PRETORIA</acronym>
  <official_title>Prospective Evaluation of a Predictive Toxicity Test Post Radiotherapy After Mastectomy With Immediate Implant Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the capacity of the NovaGray RILA Breast® test to predict the toxicity
      linked to radiotherapy and the impact of implant breast reconstruction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immediate reconstruction after mastectomy may help women with breast cancer to deal with
      their fear of mastectomy, spare them one or more second surgery and additional hospital stays
      in case of late breast reconstruction. However, in France, most patients with invasive breast
      carcinoma and treated with mastectomy are not offered immediate reconstruction. One reason is
      the need for postoperative radiotherapy for most patients (40 to 70% according to the
      centers). Indeed, radiotherapy induces side-effects which can alter the cosmetic result of
      the breast reconstruction as well as the patient's quality of life. Since 1995, a significant
      correlation is observed between the RILA test (measurement by flux cytometry of the
      lymphocyte T-CD8 apoptosis induced by radiotherapy) and the risk of occurrence of severe
      radio-induced breast fibrosis. Such accurate personalized medical care could allow
      identifying before any treatment high risk of toxicity patients and thus help establishing
      the therapeutic strategy. Identification of low-risk patients could also allow limiting
      autologous samplings and thus their associated morbidity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>For all the patients, the NovaGray RILA Breast® test will be performed within 15 days of surgery and then 12 months after the end of radiotherapy.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of a radiosensitivity test to predict capsular contracture</measure>
    <time_frame>12 months after the end of radiotherapy</time_frame>
    <description>To identify the Area Under the Curve (AUC) of the radiosensitive predictive test of Grade 3-4 capsular contracture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Capsular contracture prevalence</measure>
    <time_frame>12 Months</time_frame>
    <description>Rate of capsular contracture after radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of the dichotomized test based on the optimal threshold</measure>
    <time_frame>12 months</time_frame>
    <description>Accuracy of the test assessed by Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Precision of the radiosensitivity predictive test</measure>
    <time_frame>12 months</time_frame>
    <description>Using the time dependant AUC (AUCt) method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological prognostics factors for capsular contracture occurence</measure>
    <time_frame>12 months</time_frame>
    <description>Number and type of different biological prognostic factors of capsular contracture occurence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral prognostics factors for capsular contracture occurence</measure>
    <time_frame>12 months</time_frame>
    <description>Number and type of different tumoral prognostic factors of capsular contracture occurence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success of each surgical strategy in terms of deposit</measure>
    <time_frame>24 months</time_frame>
    <description>Number of deposit according to each reconstruction surgery (one or two step)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcomes measure</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>Cosmetic questionnaire : BREAST-Q</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes measure</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>Functional questionnaire: BREAST-Q</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction measure</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>Patient satisfaction questionnaire: BREAST-Q</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General quality of life measure</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>Quality of life questionnaire: QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific quality of life measure for breast cancer patient</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>Quality of life questionnaire for breast cancer patient: QLQ-BR23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of the test after chemotherapy</measure>
    <time_frame>12 months</time_frame>
    <description>Test score at 12 months after the end of radiotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Capsular Contracture Associated With Breast Implant</condition>
  <arm_group>
    <arm_group_label>Toxicity test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For all patients, the NovaGray RILA Breast® test will be performed within 15 days of surgery , 12 months after the end of radiotherapy and in the case of neoadjuvant chemotherapy, within 15 days of starting chemotherapy.
The test consists of a blood sample of 2x4 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovaGray RILA Breast® test</intervention_name>
    <description>The test consists of a blood sample of 2x4 mL. This test will be performed within 15 days of surgery, 12 months after the end of radiotherapy and within 15 days of starting chemotherapy in the case of neoadjuvant chemotherapy.</description>
    <arm_group_label>Toxicity test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Patients with histologically confirmed breast cancer with indication of mastectomy

          -  Indication of wall chest radiation after mastectomy

          -  Patient's agreement to receive an immediate breast reconstruction by implant in one or
             two steps, with or without a dermal or synthetic matrix (depending on the habits of
             the center)

          -  Performance Status 0-1 (Appendix 6)

          -  Consent signed before any study procedure

          -  Patient geographically accessible for follow-up

          -  Affiliated to the French national social security system

        Exclusion Criteria:

          -  Breast reconstruction with flap

          -  Inflammatory breast cancer (cT4d)

          -  Skin or parietal breast cancer (cT4 a, b or c)

          -  Metastatic patients

          -  Patients with bilateral breast cancer

          -  History of homolateral breast cancer treated with radiotherapy

          -  History of contralateral breast cancer

          -  Pregnant or breastfeeding women or women of childbearing potential unwilling to employ
             adequate contraception

          -  Legal incapacity or physical, psychological or mental status interfering with the
             patient's ability to sign the informed consent

          -  Participation in an interventional clinical study or planned participation during
             study up to 12 months post-radiotherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients with breast cancer treated by mastectomy with immediate implant breast reconstruction</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marian Gutowski</last_name>
    <role>Study Chair</role>
    <affiliation>Institut du Cancer de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre Bleuse</last_name>
    <phone>04 67 61 31 02</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie Pierre Chauvet</last_name>
      <email>mp-chauvet@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Adele Dammacco</last_name>
      <email>marie-adele.dammacco@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie Bannier</last_name>
      <email>bannierm@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marian Gutowski</last_name>
      <email>marian.gutowski@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Atlan</last_name>
      <email>michael.atlan@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Victoire Brillaud-Meflah</last_name>
      <email>victoire.brillaud-meflah@ico.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Nègre G, Balcaen T, Dast S, Sinna R, Chazard E. Breast reconstruction in France, observational study of 140,904 cases of mastectomy for breast cancer. Ann Chir Plast Esthet. 2020 Feb;65(1):36-43. doi: 10.1016/j.anplas.2019.07.014. Epub 2019 Aug 2.</citation>
    <PMID>31383624</PMID>
  </reference>
  <reference>
    <citation>Ng SK, Hare RM, Kuang RJ, Smith KM, Brown BJ, Hunter-Smith DJ. Breast Reconstruction Post Mastectomy: Patient Satisfaction and Decision Making. Ann Plast Surg. 2016 Jun;76(6):640-4. doi: 10.1097/SAP.0000000000000242.</citation>
    <PMID>25003439</PMID>
  </reference>
  <reference>
    <citation>Howes BH, Watson DI, Xu C, Fosh B, Canepa M, Dean NR. Quality of life following total mastectomy with and without reconstruction versus breast-conserving surgery for breast cancer: A case-controlled cohort study. J Plast Reconstr Aesthet Surg. 2016 Sep;69(9):1184-91. doi: 10.1016/j.bjps.2016.06.004. Epub 2016 Jun 18.</citation>
    <PMID>27406255</PMID>
  </reference>
  <reference>
    <citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717.</citation>
    <PMID>15894097</PMID>
  </reference>
  <reference>
    <citation>Ricci JA, Epstein S, Momoh AO, Lin SJ, Singhal D, Lee BT. A meta-analysis of implant-based breast reconstruction and timing of adjuvant radiation therapy. J Surg Res. 2017 Oct;218:108-116. doi: 10.1016/j.jss.2017.05.072. Epub 2017 Jun 15. Review.</citation>
    <PMID>28985836</PMID>
  </reference>
  <results_reference>
    <citation>Barry M, Kell MR. Radiotherapy and breast reconstruction: a meta-analysis. Breast Cancer Res Treat. 2011 May;127(1):15-22. doi: 10.1007/s10549-011-1401-x. Epub 2011 Feb 20. Review.</citation>
    <PMID>21336948</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contracture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

